Akros Pharma

Akros Pharma is a clinical-stage biotechnology company serving as the US development arm of Shionogi. Its pipeline consists of seven small molecule drug candidates, primarily in Phase 1 and Phase 2 trials, targeting autoimmune diseases, type 2 diabetes, chronic heart failure, neurodegenerative diseases, pulmonary arterial hypertension, and peripheral artery disease. The company leverages Shionogi's discovery engine and is led by a management team with deep expertise in clinical development, regulatory affairs, and intellectual property. As a private, subsidiary entity, its financial position and strategic direction are intrinsically linked to its parent company.

Acts as development vehicle for small molecule inhibitors discovered by parent company Shionogi; focused on targeted inhibitors of ITK, SGLT1, PDHK, Pim-1, NLRP3, and H-PGDS pathways.

Faces competition from large pharma and biotech firms across all indications. Key competitive arenas include NLRP3 inhibitors (e.g., from NodThera, Ventus), SGLT1 inhibitors, and ITK inhibitors. Success will require demonstrating superior efficacy or safety profiles.